RLFTF Stock - Relief Therapeutics Holding AG
Unlock GoAI Insights for RLFTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.42M | $6.03M | $6.08M | $3.32M | N/A |
| Gross Profit | $5.84M | $4.30M | $4.83M | $2.57M | $-13,672,000 |
| Gross Margin | 69.4% | 71.2% | 79.4% | 77.4% | N/A |
| Operating Income | $-18,885,000 | $-110,828,000 | $-52,040,000 | $-34,306,000 | $-9,085,000 |
| Net Income | $-17,119,000 | $-98,181,000 | $-50,790,000 | $-34,705,000 | $-7,828,000 |
| Net Margin | -203.4% | -1627.4% | -835.2% | -1045.0% | N/A |
| EPS | $-1.37 | $-8.35 | $-4.80 | $-3.86 | $-1.30 |
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.
Visit WebsiteEarnings History & Surprises
RLFTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 8, 2026 | — | — | — | — |
Q3 2025 | Sep 1, 2025 | — | $-0.45 | — | — |
Q2 2025 | Apr 10, 2025 | — | $-1.10 | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.41 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-3.88 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-5.68 | — | — |
Q2 2023 | May 12, 2023 | — | $-2.44 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-2.66 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-2.30 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.91 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-3.21 | — | — |
Q2 2020 | Jun 30, 2020 | — | $1.62 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.33 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.11 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.07 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.37 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.22 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-3.43 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.17 | — | — |
Latest News
Frequently Asked Questions about RLFTF
What is RLFTF's current stock price?
What is the analyst price target for RLFTF?
What sector is Relief Therapeutics Holding AG in?
What is RLFTF's market cap?
Does RLFTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RLFTF for comparison